EDGAR·FLOW

Neumora Therapeutics, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 48/100
What the filing says
Neumora submitted an IND application for NMRA-215 (NLRP3 inhibitor) for obesity/cardiometabolic disease to the FDA. NMRA-511 (V1aR antagonist) Phase 1 MAD expansion showed dose-proportional exposure increases at 30 mg BID with no serious adverse events, potentially building on Phase 1b efficacy. Cash and equivalents declined from $182.5M (Dec 31, 2025) to $85.7M (Sept 30, 2026)—a 53% burn in nine months; Q3 2026 net loss was $34.4M vs. $56.8M in Q3 2025; R&D spending fell to $22.6M from $40.5M YoY.
Why this rating

IND submission is pipeline progress; however, 53% cash depletion in 9 months (burn ~$97M) relative to $63M market cap signals existential funding urgency. No partnership/financing announced. Positive clinical data offset by severe liquidity constraint.

View original filing on SEC.gov ↗ NMRA · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.